Supernus Pharmaceuticals, Inc.: Parkinson Disease trials
The registry lists 13 Parkinson Disease studies with Supernus Pharmaceuticals, Inc. as lead sponsor. 1 are open to participants now and 11 have results posted.
Phase 2 3Phase 3 7Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:RecruitingNCT07219927
- A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentCompletedNCT05318937Phase 2Results posted
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)CompletedNCT04476017Phase 2Results posted
- Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)CompletedNCT03944785Results posted
- Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®TerminatedNCT02549573Phase 4Results posted
- Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaCompletedNCT02274766Phase 3Results posted
- Open-Label Safety Study of ADS-5102 in PD Patients With LIDCompletedNCT02202551Phase 3Results posted
- Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.TerminatedNCT02153645Phase 3Results posted
- Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDTerminatedNCT02153632Phase 3Results posted
- ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)CompletedNCT02136914Phase 3Results posted
- Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)CompletedNCT01770145Phase 4Results posted
- Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)CompletedNCT01397422Phase 2/3Results posted
- Infusion of Apomorphine: Long-term Safety StudyActive, not recruitingNCT02339064Phase 3